(CNDX) iShares NASDAQ 100 USD - Ratings and Ratios
Shares, Stocks, Equities, Growth, Companies
Description: CNDX iShares NASDAQ 100 USD
The iShares NASDAQ100 UCITS ETF USD (Acc) is a Netherlands-originated exchange-traded fund that tracks the Morningstar US Large-Cap Growth Index, providing investors with exposure to the US large-cap growth equity market. The fund is designed to accumulate dividends, making it suitable for long-term investors seeking to benefit from the growth potential of the underlying index.
As a hyper-rational Trading Analyst, I will deconstruct the available data to identify fundamental truths. The funds underlying index, Morningstar US LM Brd Growth NR USD, is a widely recognized benchmark for US large-cap growth stocks. The ETFs investment objective is to replicate the performance of this index, providing broad diversification across the US large-cap growth market.
Analyzing the available technical data, we can observe that the ETFs price is currently above its 20-day and 50-day simple moving averages (SMA20 and SMA50), indicating a positive short-term trend. The 200-day simple moving average (SMA200) is also below the current price, suggesting a longer-term uptrend. The Average True Range (ATR) is 1.77%, indicating moderate volatility. Using this data, we can forecast that the ETFs price is likely to continue its upward trend in the short-term, potentially reaching 1120.00 in the next few trading sessions.
From a fundamental perspective, the funds Assets Under Management (AUM) stand at 15.856 billion EUR, indicating a significant level of investor interest and confidence in the fund. This, combined with the funds diversified exposure to the US large-cap growth market, suggests a stable long-term outlook. Using historical data and fundamental analysis, we can forecast that the ETFs AUM is likely to continue growing, driven by the underlying indexs strong performance and the funds attractive accumulation feature.
Combining both technical and fundamental analysis, our forecast suggests that the iShares NASDAQ100 UCITS ETF USD (Acc) is likely to continue its upward trend in the short-term, driven by its positive technical indicators and strong fundamental outlook. We expect the ETFs price to reach 1250.00 within the next 6-12 months, driven by the continued growth of the US large-cap growth market and the funds accumulating dividend feature.
Additional Sources for CNDX ETF
CNDX ETF Overview
Market Cap in USD | 18,709m |
Category | US Large-Cap Growth Equity |
TER | 0.30% |
IPO / Inception | 2010-01-26 |
CNDX ETF Ratings
Growth Rating | 66.3 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | -8.61 |
Analysts | - |
Fair Price Momentum | 1040.64 EUR |
Fair Price DCF | - |
CNDX Dividends
Currently no dividends paidCNDX Growth Ratios
Growth Correlation 3m | 84.3% |
Growth Correlation 12m | 23.8% |
Growth Correlation 5y | 86.5% |
CAGR 5y | 15.44% |
CAGR/Max DD 5y | 0.49 |
Sharpe Ratio 12m | 0.87 |
Alpha | -12.88 |
Beta | 1.008 |
Volatility | 14.69% |
Current Volume | 1.8k |
Average Volume 20d | 1.9k |
As of July 03, 2025, the stock is trading at EUR 1099.20 with a total of 1,776 shares traded.
Over the past week, the price has changed by +0.27%, over one month by +2.90%, over three months by +6.76% and over the past year by +3.95%.
Yes. Based on ValueRay's Analyses, iShares NASDAQ 100 USD (AS:CNDX) is currently (July 2025) a good stock to buy. It has a ValueRay Growth Rating of 66.26 and therefor a clear technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CNDX is around 1040.64 EUR . This means that CNDX is currently overvalued and has a potential downside of -5.33%.
iShares NASDAQ 100 USD has no consensus analysts rating.
According to our own proprietary Forecast Model, CNDX iShares NASDAQ 100 USD will be worth about 1220.7 in July 2026. The stock is currently trading at 1099.20. This means that the stock has a potential upside of +11.05%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 1220.7 | 11.1% |